TICKERNERD
Menu
MGTXMGTXHealthcare · Biotechnology

MGTX Stock Forecast: Meiragtx Holdings plc Price Predictions for 2026-2027

Last close, 8 Oct 2026
$11
−2.96% on the day

The 8 Wall Street analysts covering Meiragtx Holdings plc hold a median 12-month price target of $24 — +123.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.0B
Ticker Nerd rank
83 / 100
Median analyst target
$24
Analysts covering
8
Revenue$321.4M+8608.6% y/y
Operating income$244.4M
Net income$160.7M
Free cash flow−$62.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.5%
1M
−22.4%
YTD
+32.1%
1Y
+27.1%
From 52W high
−29.9%
From 52W low
+50.2%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Meiragtx Holdings plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Value
97
Revisions
91
Quality
78
Momentum
74
Volatility
59
Size
44
Accruals
12
Issuance
12

Growth (100): Sales and profits are climbing, and climbing faster than before.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26MGTXHigh $50Median $24Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $16Median $24High $50

The green dot is the last close — the median target sits +123.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026Goldman SachsInitiatesNeutral$16
14 Aug 2026RBC CapitalMaintainsOutperform—
14 Aug 2026RBC CapitalMaintainsOutperform$26 → $27
8 July 2026HC Wainwright & Co.ReiteratesBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy$20
8 July 2026RBC CapitalMaintainsOutperform—
8 July 2026RBC CapitalMaintainsOutperform$25 → $26
15 May 2026RBC CapitalMaintainsOutperform—
22 Apr 2026Piper SandlerMaintainsOverweight—
17 Apr 2026RBC CapitalMaintainsOutperform—
1 Apr 2026Evercore ISI GroupMaintainsOutperform—
27 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Chardan CapitalMaintainsBuy—
27 Mar 2026Piper SandlerMaintainsOverweight—
24 Nov 2025HC Wainwright & Co.InitiatesBuy—
14 Nov 2025Chardan CapitalMaintainsBuy—
14 Nov 2025RBC CapitalMaintainsOutperform—
11 Nov 2025Chardan CapitalMaintainsBuy—
11 Nov 2025Piper SandlerMaintainsOverweight—
21 Oct 2025Raymond JamesInitiatesStrong Buy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Meiragtx Holdings plc returned +27.1% against +16.2% for the S&P 500, dividends included.

MGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26MGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Meiragtx Holdings plc (MGTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.1×

Cheaper than 52% of US stocks

Price / sales
2.5×

Cheaper than 46% of US stocks

Price / book
4.6×

Cheaper than 22% of US stocks

EV / EBITDA
5.1×

Cheaper than 53% of US stocks

Growth & margins
Revenue growth (YoY)
8608.6%

Higher than 99% of US stocks

Earnings growth (YoY)
8608.6%

Higher than 99% of US stocks

Gross margin
97.8%

Higher than 99% of US stocks

Operating margin
76.0%

Higher than 99% of US stocks

Net margin
19.9%

Higher than 82% of US stocks

Returns & dividend
Return on equity
72.2%

Higher than 95% of US stocks

Return on assets
38.7%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Meiragtx Holdings plc (MGTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Meiragtx Holdings plc has a market value of $1.0B and an enterprise value of $1.0B.

  • Revenue in the twelve months to 30 June 2026: $397.5M. The latest quarter grew 8608.6% year on year.

  • Net income over the same four quarters: $78.9M, a 19.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$14.2M.

  • Shares outstanding: 94.2M.

  • Trailing P/E: 12.1×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Meiragtx Holdings plc employs 393 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

MGTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGTXMeiragtx Holdings plc$1.0B
83
AKTSAktis Oncology, Inc.$980.6M
1
CGEMCullinan Therapeutics, Inc.$950.1M
67
SVRASavara, Inc.$949.9M
33
SPTXSeaport Therapeutics, Inc.$949.7M
1
LTGOLatigo Biotherapeutics, Inc.$935.3M
1
ANROAlto Neuroscience, Inc.$934.1M
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Meiragtx Holdings plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGTX news & analysis

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

GlobeNewsWire · 23 Sept 2026positive

MeiraGTx Holdings plc announced the appointment of Alan M. Sebulsky, an accomplished healthcare portfolio manager, to its Board of Directors. The appointment was announced via a press release dated September 23, 2026, from London and New York.

Why it matters — Adding an experienced healthcare portfolio manager to the board brings financial and industry expertise that could support the company's strategic direction as a clinical-stage genetic medicines firm.

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

PRNewsWire · 26 Aug 2026neutral

Graviton BioScience Corporation announced the publication in Signal Transduction and Targeted Therapy of positive Phase 1b trial results for GV101 (TDI01), a selective ROCK2 inhibitor, in chronic Graft versus Host Disease (cGvHD). The therapy showed best overall response rates at 400 mg and 200 mg at 24 weeks in patients who had failed at least two prior lines of therapy, with the 24-week rate exceeding published 6-month rates for approved steroid-refractory cGvHD therapies.

Why it matters — An MGTX watcher would care because this news reflects progress in the competitive therapeutic landscape for cGvHD treatment by a separate biopharmaceutical company.

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 13 Aug 2026positive

MeiraGTx Holdings reported Q2 earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share in the year-ago quarter.

Why it matters — A MGTX watcher would care because the company significantly exceeded analyst earnings expectations and improved sharply versus the prior-year loss.

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

GlobeNewsWire · 13 Aug 2026positive

MeiraGTx reported second quarter 2026 financial and operational results, announcing FDA Breakthrough Therapy Designation and positive three-year Phase 1 data for AAV2-hAQP1, the completed $25 million acquisition of bota-vec from Johnson & Johnson for XLRP, a $100 million equity financing, and an up to $400 million strategic investment from Oberland Capital. The company stated it anticipates global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 in mid-2027.

Why it matters — The quarter marks key clinical and regulatory progress toward commercialization, with breakthrough designation for AAV2-hAQP1, the finalised bota-vec acquisition, and additional financing to support development of both programmes.

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

PRNewsWire · 11 Aug 2026neutral

Graviton BioScience announced that the U.S. FDA cleared its Investigational New Drug (IND) application on August 7, 2026, for GV101, a novel capsule formulation with improved pharmacokinetics and oral availability, intended for the treatment of Friedreich's ataxia. The clearance advances this formulation toward human trials.

Why it matters — This IND clearance signals progress by a company developing Friedreich's ataxia treatments, a therapeutic area relevant to Meiragtx Holdings plc watchers given the company's focus on Friedreich's ataxia therapy development.

FAQ

Frequently asked questions about MGTX stock

What is the MGTX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Meiragtx Holdings plc have a median 12-month price target of $24, with estimates ranging from $16 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGTX stock a buy right now?

Of the 8 analysts covering Meiragtx Holdings plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Meiragtx Holdings plc 83 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGTX?

As at 8 Oct 2026, Meiragtx Holdings plc ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

Will MGTX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +123.8% from the last close, and Ticker Nerd's factor model ranks Meiragtx Holdings plc 83 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGTX stock forecast for 2030?

No analyst covering Meiragtx Holdings plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $50 over the next 12 months.

How has MGTX stock performed over the past year?

Meiragtx Holdings plc returned +27.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Meiragtx Holdings plc do?

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs.

What is the latest news on MGTX?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors". MeiraGTx Holdings plc announced the appointment of Alan M. Sebulsky, an accomplished healthcare portfolio manager, to its Board of Directors. The appointment was announced via a press release dated September 23, 2026, from London and New York.

Company

About Meiragtx Holdings plc.

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.

CEO Dr. Alexandria Forbes Ph.D. · 393 employees · United States · https://www.meiragtx.com